ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Long-term Clinical Outcomes After Hospitalization for Acute Respiratory Illness Due to Respiratory Syncytial Virus.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Healthcare resource use and costs following RSV-related hospitalizations among US adults aged 50 years and older.Human vaccines & immunotherapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute respiratory illnesses (ARIs) can be severe in older adults and adults with chronic conditions. We compared long-term outcomes of United States patients aged ≥50 years with ≥1 hospitalized ARI due to respiratory syncytial virus (RSV-ARI cohort) versus controls without ARI (control cohort) and patients with ≥1 hospitalized influenza-ARI (influenza-ARI cohort).
methodsThis retrospective study used 1 October 2015-30 June 2023 claims data to evaluate clinical outcomes across the three cohorts. The index date was defined as the start of an ARI episode. Cumulative incidence functions assessed risks of readmission, all-cause mortality, myocardial infarction (MI), asthma and chronic obstructive pulmonary disease (COPD) exacerbation, and hospitalization due to heart failure (HHF); adjusted risks were compared using multivariable regression models.
resultsA total of 14 759, 77 468, and 73 795 patients were selected into the RSV-ARI, influenza-ARI, and control cohorts, respectively. The RSV-ARI cohort had a substantially higher adjusted risk of all-cause mortality than controls, with the highest adjusted hazard ratio (95% confidence interval) 0-30 days post-index (10.772 [9.190, 12.627]). MI risk followed a pattern similar to all-cause mortality. Adjusted risks of asthma exacerbation, COPD exacerbation, and HHF were significantly higher in the RSV-ARI cohort than controls, and similar between RSV-ARI and influenza-ARI cohorts.
conclusionsRSV-ARI had considerable long-term impact on clinical outcomes, with measurable increases in outcomes associated with RSV-ARI when compared with controls, and similar outcomes compared to influenza-ARI. These findings can inform RSV prevention efforts and support future research on the long-term impact of RSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.